Refuge Biotechnologies develops intelligent cell therapeutics engineered to make decisions inside patients using its receptor‑dCas platform, which employs a mutated or dead Cas9 (dCas) to enable precision CRISPR activation and interference. The company is led by co‑founder and CEO Bing C. Wang, Ph.D., with Francesco Marincola, M.D., newly appointed as chief scientific officer. Refuge intends to use the financing to advance cell therapies built on its receptor‑dCas platform and to support collaborative research with partners. As part of the financing, lead investors will have an exclusive right to negotiate development and commercialization rights for therapies using the platform in China. Refuge and 3SBio will collaborate on research to develop programmed cell therapeutics that can produce therapeutic proteins inside a patient’s body. The company is based in Menlo Park, California.

Total raised

$25M

Funding rounds

1

Latest round

Series B

Latest activity

May 2018